Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) at a Comprehensive Cancer Center
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Incidence of grade III and IV hypersensitivity reactions
Every 15 minutes from start of infusion until completion
Jeffrey Jones, M.D., M.P.H.
Ohio State University
United States: Institutional Review Board
|The Ohio State University Comprehensive Cancer Center||Columbus, Ohio 43210|